Aimovig (erenumab-aooe) is a prescription drug used to help prevent migraine episodes in adults. It’s given as an injection under the skin. This drug isn’t known to interact with alcohol, other ...

Aimovig can cause side effects ranging from mild to serious. Common side effects include muscle cramps, constipation, and injection site reactions. Severe constipation requiring hospital treatment, ...

After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study showed the ...

TRENTON, N.J. (AP) - U.S. regulators Thursday approved the first drug designed to prevent chronic migraines. The Food and Drug Administration's action clears the monthly shot Aimovig (AIM'-oh-vig) for ...

The first antibody treatment to prevent migraine (Aimovig), produced by Novartis, is on the cusp of approval. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP ...

Please provide your email address to receive an email when new articles are posted on . Patients with migraine who switched from Aimovig to Emgality to treat their headaches reported similar ...

Amgen's migraine prevention drug Aimovig, just approved in May, is riding a rising wave of early demand—and that's a good thing, not just for Amgen and its partner Novartis, but for other forthcoming ...

If approved by the FDA, Aimovig will be the first monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor specifically intended for migraine prophylaxis. Amgen announced that ...

Amgen Inc. AMGN has announced full results from the phase IIIb study on its anti-CGRP receptor antibody, Aimovig (erenumab), which once again demonstrates a significant reduction in migraine frequency ...

A new drug designed to fight chronic migraine attacks could be on the market this week. The FDA has approved Aimovig. It's designed to reduce the frequency of migraines that affect about 12-percent of ...

Swiss pharma giant Novartis AGNVS announced it is suing partner Amgen AMGN. Both the companies had a development and worldwide commercialization agreement for migraine drug, Aimovig (erenumab).

The first antibody treatment to prevent migraine (Aimovig), produced by Novartis, is on the cusp of approval. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP ...